ID   DOC2B_RAT               Reviewed;         412 AA.
AC   P70610;
DT   31-AUG-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 2.
DT   22-JUL-2015, entry version 103.
DE   RecName: Full=Double C2-like domain-containing protein beta;
DE            Short=Doc2-beta;
GN   Name=Doc2b;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Brain;
RX   PubMed=9115738; DOI=10.1016/S0896-6273(00)81245-3;
RA   Verhage M., de Vries K.J., Roeshol H., Burbach J.P., Gispen W.H.,
RA   Suedhof T.C.;
RT   "DOC2 proteins in rat brain: complementary distribution and proposed
RT   function as vesicular adapter proteins in early stages of secretion.";
RL   Neuron 18:453-461(1997).
RN   [2]
RP   INTERACTION WITH DYNLT1.
RC   STRAIN=Sprague-Dawley; TISSUE=Brain;
RX   PubMed=9804756; DOI=10.1074/jbc.273.46.30065;
RA   Nagano F., Orita S., Sasaki T., Naito A., Sakaguchi G., Maeda M.,
RA   Watanabe T., Kominami E., Uchiyama Y., Takai Y.;
RT   "Interaction of Doc2 with tctex-1, a light chain of cytoplasmic
RT   dynein. Implication in dynein-dependent vesicle transport.";
RL   J. Biol. Chem. 273:30065-30068(1998).
RN   [3]
RP   INTERACTION WITH UNC13A, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   15-GLN--ILE-20.
RX   PubMed=15033971; DOI=10.1074/jbc.M400731200;
RA   Groffen A.J., Brian E.C., Dudok J.J., Kampmeijer J., Toonen R.F.,
RA   Verhage M.;
RT   "Ca(2+)-induced recruitment of the secretory vesicle protein DOC2B to
RT   the target membrane.";
RL   J. Biol. Chem. 279:23740-23747(2004).
RN   [4]
RP   FUNCTION, PHOSPHOLIPID-BINDING, MUTAGENESIS OF ASP-218 AND ASP-220,
RP   AND INTERACTION WITH STX1A AND SNAP25.
RX   PubMed=18596155; DOI=10.1523/JNEUROSCI.0538-08.2008;
RA   Friedrich R., Groffen A.J., Connell E., van Weering J.R., Gutman O.,
RA   Henis Y.I., Davletov B., Ashery U.;
RT   "DOC2B acts as a calcium switch and enhances vesicle fusion.";
RL   J. Neurosci. 28:6794-6806(2008).
RN   [5]
RP   FUNCTION, PHOSPHOLIPID-BINDING, INTERACTION WITH SNARE COMPLEX, AND
RP   MUTAGENESIS OF HIS-158; PHE-222; LYS-237; LYS-319 AND ILE-360.
RX   PubMed=20150444; DOI=10.1126/science.1183765;
RA   Groffen A.J., Martens S., Diez Arazola R., Cornelisse L.N.,
RA   Lozovaya N., de Jong A.P., Goriounova N.A., Habets R.L., Takai Y.,
RA   Borst J.G., Brose N., McMahon H.T., Verhage M.;
RT   "Doc2b is a high-affinity Ca2+ sensor for spontaneous neurotransmitter
RT   release.";
RL   Science 327:1614-1618(2010).
CC   -!- FUNCTION: Calcium sensor which positively regulates SNARE-
CC       dependent fusion of vesicles with membranes. Binds phospholipids
CC       in a calcium-dependent manner and may act at the priming stage of
CC       fusion by modifying membrane curvature to stimulate fusion.
CC       Involved in calcium-triggered exocytosis in chromaffin cells and
CC       calcium-dependent spontaneous release of neurotransmitter in
CC       absence of action potentials in neuronal cells. Involved both in
CC       glucose-stimulated insulin secretion in pancreatic cells and
CC       insulin-dependent GLUT4 transport to the plasma membrane in
CC       adipocytes. {ECO:0000269|PubMed:18596155,
CC       ECO:0000269|PubMed:20150444}.
CC   -!- SUBUNIT: Interacts with STX4; the interaction is calcium-
CC       dependent, increased by insulin and glucose, and mediates vesicle
CC       fusion with plasma membrane in pancreatic cells and adipocytes.
CC       Interacts with STXBP3; the interaction is direct, occurs at the
CC       cell membrane and regulates glucose-stimulated insulin secretion
CC       (By similarity). Interacts with cytoplasmic dynein light chain
CC       DYNLT1. Interacts with the SNARE (soluble N-ethylmaleimide-
CC       sensitive factor attached protein receptor) complex composed of
CC       SNAP25, STX1A and VAMP2; the interaction is calcium-dependent and
CC       competitive with SYT1. May interact with UNC13A; the interaction
CC       mediates targeting to the plasma membrane. {ECO:0000250,
CC       ECO:0000269|PubMed:15033971, ECO:0000269|PubMed:18596155,
CC       ECO:0000269|PubMed:20150444, ECO:0000269|PubMed:9804756}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Cytoplasmic granule
CC       {ECO:0000250}. Cell membrane; Peripheral membrane protein.
CC       Note=Translocates to the plasma membrane in a calcium-dependent
CC       manner.
CC   -!- TISSUE SPECIFICITY: Expressed in brain; highly enriched in
CC       neurons. {ECO:0000269|PubMed:9115738}.
CC   -!- DOMAIN: C2 domain 1 is involved in binding calcium and
CC       phospholipids. C2 domain 2 may also play a role in the calcium-
CC       dependent targeting to membranes (By similarity). {ECO:0000250}.
CC   -!- SIMILARITY: Contains 2 C2 domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00041}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U70778; AAB47747.2; -; mRNA.
DR   RefSeq; NP_112404.1; NM_031142.1.
DR   UniGene; Rn.10689; -.
DR   PDB; 4LCV; X-ray; 2.00 A; A/B/C/D=125-255.
DR   PDB; 4LDC; X-ray; 1.26 A; A=265-412.
DR   PDBsum; 4LCV; -.
DR   PDBsum; 4LDC; -.
DR   ProteinModelPortal; P70610; -.
DR   SMR; P70610; 127-252, 260-404.
DR   GeneID; 81820; -.
DR   KEGG; rno:81820; -.
DR   CTD; 8447; -.
DR   RGD; 620519; Doc2b.
DR   eggNOG; NOG247952; -.
DR   HOGENOM; HOG000232127; -.
DR   HOVERGEN; HBG051388; -.
DR   InParanoid; P70610; -.
DR   PhylomeDB; P70610; -.
DR   NextBio; 615739; -.
DR   PRO; PR:P70610; -.
DR   Proteomes; UP000002494; Unplaced.
DR   Genevisible; P70610; RN.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005509; F:calcium ion binding; IBA:GO_Central.
DR   GO; GO:0005544; F:calcium-dependent phospholipid binding; IDA:UniProtKB.
DR   GO; GO:0030276; F:clathrin binding; IBA:GO_Central.
DR   GO; GO:0019905; F:syntaxin binding; IBA:GO_Central.
DR   GO; GO:0048791; P:calcium ion-dependent exocytosis of neurotransmitter; IDA:UniProtKB.
DR   GO; GO:0006887; P:exocytosis; IEP:RGD.
DR   GO; GO:0045956; P:positive regulation of calcium ion-dependent exocytosis; IDA:UniProtKB.
DR   GO; GO:0032024; P:positive regulation of insulin secretion; ISS:UniProtKB.
DR   GO; GO:0031340; P:positive regulation of vesicle fusion; IDA:UniProtKB.
DR   GO; GO:0008104; P:protein localization; ISS:UniProtKB.
DR   GO; GO:0016079; P:synaptic vesicle exocytosis; IBA:GO_Central.
DR   Gene3D; 2.60.40.150; -; 2.
DR   InterPro; IPR000008; C2_dom.
DR   InterPro; IPR014638; Doc2.
DR   InterPro; IPR030534; Doc2b.
DR   InterPro; IPR001565; Synaptotagmin.
DR   PANTHER; PTHR10024:SF173; PTHR10024:SF173; 1.
DR   Pfam; PF00168; C2; 2.
DR   PIRSF; PIRSF036931; Doc2; 1.
DR   PRINTS; PR00360; C2DOMAIN.
DR   PRINTS; PR00399; SYNAPTOTAGMN.
DR   SMART; SM00239; C2; 2.
DR   SUPFAM; SSF49562; SSF49562; 2.
DR   PROSITE; PS50004; C2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Calcium; Calcium/phospholipid-binding; Cell membrane;
KW   Complete proteome; Cytoplasm; Membrane; Reference proteome; Repeat.
FT   CHAIN         1    412       Double C2-like domain-containing protein
FT                                beta.
FT                                /FTId=PRO_0000079970.
FT   DOMAIN      128    232       C2 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00041}.
FT   DOMAIN      268    371       C2 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00041}.
FT   REGION        1     90       Mediates interaction with DYNLT1.
FT                                {ECO:0000250}.
FT   REGION        1     36       Negatively regulates targeting to plasma
FT                                membrane. {ECO:0000250}.
FT   REGION      257    375       Mediates interaction with STXBP3.
FT                                {ECO:0000250}.
FT   MUTAGEN      15     20       QEHMAI->YKDWAF: Prevents diacylglycerol-
FT                                induced localization to the plasma
FT                                membrane. Probably prevents interaction
FT                                with UNC13A.
FT                                {ECO:0000269|PubMed:15033971}.
FT   MUTAGEN     158    158       H->A: Loss of calcium-dependent binding
FT                                to liposomes and altered fusion-promoting
FT                                activity; when associated with A-222 and
FT                                A-360. {ECO:0000269|PubMed:20150444}.
FT   MUTAGEN     218    218       D->N: Binds liposomes in a calcium-
FT                                independent manner; when associated with
FT                                N-220. {ECO:0000269|PubMed:18596155}.
FT   MUTAGEN     220    220       D->N: Binds liposomes in a calcium-
FT                                independent manner; when associated with
FT                                N-218. {ECO:0000269|PubMed:18596155}.
FT   MUTAGEN     222    222       F->A: Loss of calcium-dependent binding
FT                                to liposomes and altered fusion-promoting
FT                                activity; when associated with A-158 and
FT                                A-360. {ECO:0000269|PubMed:20150444}.
FT   MUTAGEN     237    237       K->E: Loss of calcium-independent binding
FT                                to liposomes. Loss of interaction with
FT                                the SNARE complex and altered fusion-
FT                                promoting activity; when associated with
FT                                E-319. {ECO:0000269|PubMed:20150444}.
FT   MUTAGEN     319    319       K->E: Loss of calcium-independent binding
FT                                to liposomes. Loss of interaction with
FT                                the SNARE complex and altered fusion-
FT                                promoting activity; when associated with
FT                                E-237. {ECO:0000269|PubMed:20150444}.
FT   MUTAGEN     360    360       I->A: Loss of calcium-dependent binding
FT                                to liposomes and altered fusion-promoting
FT                                activity; when associated with A-158 and
FT                                A-222. {ECO:0000269|PubMed:20150444}.
FT   STRAND      129    137       {ECO:0000244|PDB:4LCV}.
FT   HELIX       138    140       {ECO:0000244|PDB:4LCV}.
FT   STRAND      142    152       {ECO:0000244|PDB:4LCV}.
FT   STRAND      164    172       {ECO:0000244|PDB:4LCV}.
FT   HELIX       176    178       {ECO:0000244|PDB:4LCV}.
FT   STRAND      179    181       {ECO:0000244|PDB:4LCV}.
FT   STRAND      192    199       {ECO:0000244|PDB:4LCV}.
FT   HELIX       204    209       {ECO:0000244|PDB:4LCV}.
FT   STRAND      211    218       {ECO:0000244|PDB:4LCV}.
FT   STRAND      226    234       {ECO:0000244|PDB:4LCV}.
FT   HELIX       235    237       {ECO:0000244|PDB:4LCV}.
FT   STRAND      244    249       {ECO:0000244|PDB:4LCV}.
FT   STRAND      266    277       {ECO:0000244|PDB:4LDC}.
FT   TURN        278    281       {ECO:0000244|PDB:4LDC}.
FT   STRAND      282    292       {ECO:0000244|PDB:4LDC}.
FT   STRAND      304    312       {ECO:0000244|PDB:4LDC}.
FT   STRAND      332    340       {ECO:0000244|PDB:4LDC}.
FT   HELIX       343    348       {ECO:0000244|PDB:4LDC}.
FT   STRAND      350    357       {ECO:0000244|PDB:4LDC}.
FT   STRAND      360    362       {ECO:0000244|PDB:4LDC}.
FT   STRAND      365    373       {ECO:0000244|PDB:4LDC}.
FT   HELIX       378    389       {ECO:0000244|PDB:4LDC}.
FT   STRAND      395    403       {ECO:0000244|PDB:4LDC}.
SQ   SEQUENCE   412 AA;  45841 MW;  61595BC6886F1012 CRC64;
     MTLRRRGEKA TISIQEHMAI DVCPGPIRPI KQISDYFPRF PRGLPPTAAP RASAPPDAPA
     RSPAATAGPR SPSDGARDDD EDVDQLFGAY GASPGPSPGP SPVRPPAKPP EDEPDADGYE
     SDDCTALGTL DFSLLYDQEN NALHCTISKA KGLKPMDHNG LADPYVKLHL LPGASKANKL
     RTKTLRNTLN PSWNETLTYY GITDEDMIRK TLRISVCDED KFRHNEFIGE TRVPLKKLKP
     NHTKTFSICL EKQLPVDKAE DKSLEERGRI LISLKYSSQK QGLLVGIVRC AHLAAMDANG
     YSDPYVKTYL KPDVDKKSKH KTAVKKKTLN PEFNEEFCYE IKHGDLAKKT LEVTVWDYDI
     GKSNDFIGGV VLGINAKGER LKHWFDCLKN KDKRIERWHT LTNEIPGAVL SD
//
